Today, Kezar Life Sciences announced topline results from the PRESIDIO study, evaluating the efficacy and safety of zetomipzomib in dermatomyositis and polymyositis. In this study, most patients experienced a clinically meaningful improvement however, zetomipzomib did not demonstrate a significant differentiation from the placebo. We will learn more from this study with additional deeper analysis in…
Continue Reading
In 2022, we will launch this interactive community awareness event in six local communities across the country where an estimated more than 40,000 dedicated participants will work to raise funds to continue our critical work. Participate as an individual or gather your friends, family, and co-workers to form a team – build awareness, fundraise, and…
Continue Reading
Celebrating Community – Click here to join
Continue Reading
Click here for more details
Continue Reading
Click here to register
Continue Reading